Study Design and Participants
From January 2014 to December 2015, 161 patients with unilateral SSNHL accompanied by newly developed tinnitus who were hospitalized in the Department of Otorhinolaryngology, Peking University People’s Hospital, were enrolled. All of the patients’ hearing was assessed by the same doctor. After admission, treatments were applied in accordance with the Chinese Guideline for Sudden Deafness(17). Systemic corticosteroids and hemodilution agents were administered as therapeutic measures. All patients received 40 mg of intravenous methylprednisolone for 5 consecutive days and hemodilution agents for 10 days, including 87.5 mg of intravenous EGb-761(Dr. Willmar Schwabe GmbH & Co., Germany) every day and 5 BU of intravenous batroxobin (Beijing Tobishi Pharmaceutical Co.), the first dose was doubled, and every other day based on fibrinogen levels.